Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study

Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study

We designed a placebo controlled, double-blind, randomized, dose-finding phase II study on OMT-28 in the maintenance of sinus rhythm after electrical cardioversion (DCC) in patients with persistent atrial fibrillation (PROMISE-AF). OMT-28 is a first-in-class, synthetic analog of 17,18-epoxyeicosatet...

Full description

Bibliographic Details
Main Authors: Sarah Berlin, Andreas Goette, Luciana Summo, Janine Lossie, Alexander Gebauer, Naab Al-Saady, Leonardo Calo, Gerald Naccarelli, Wolf-Hagen Schunck, Robert Fischer, A.John Camm, Dobromir Dobrev
Format: Article
Language:English
Published: Elsevier 2020-08-01
Series:International Journal of Cardiology: Heart & Vasculature
Subjects:
OMT-28
Omega-3 epoxyeicosanoid
Atrial fibrillation
Phase II
Online Access:http://www.sciencedirect.com/science/article/pii/S2352906720302712

Internet

http://www.sciencedirect.com/science/article/pii/S2352906720302712

Similar Items